Inbiomotion is a company that focuses on the development and commercialization of a biomarker that predicts metastasis. It uses a diagnostic assay that is based on a single gene biomarker helping to identify early-stage breast cancer. In addition, the generated data can be used to estimate the risk of metastases relapse from primary tumors.